| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary biological targets of 6-methylpicolinic acid are not extensively characterized. However, picolinic acid, the parent compound, is known to act as a chelator of metal ions such as zinc and iron, and has been studied as an inhibitor of zinc finger proteins and as an immunomodulatory agent. Picolinic acid derivatives have been investigated for their activity against enveloped viruses by interfering with viral entry processes. 6-Methylpicolinic acid may share similar metal-chelating properties and potential for zinc finger protein modulation, but specific target identification for this methylated analog requires further experimental validation.
|
|---|---|
| ln Vitro |
In vitro, 6-methylpicolinic acid is primarily used as a chemical reagent and synthetic intermediate. Picolinic acid derivatives have demonstrated activity in cell-based assays including antiviral assays against HIV, influenza, and other enveloped viruses through mechanisms involving metal chelation and interference with viral envelope fusion. They have also been studied for immunomodulatory effects in macrophage and T-cell cultures. However, specific in vitro activity data for 6-methylpicolinic acid itself are not well-documented in the literature. The compound's carboxylic acid and pyridine nitrogen provide metal-chelating functionality that can be evaluated in vitro using colorimetric or fluorometric metal-binding assays.
|
| ln Vivo |
In vivo data for 6-methylpicolinic acid as a standalone compound are not available. The compound is primarily a synthetic intermediate rather than a directly administered drug. Picolinic acid, the parent compound, has been studied in animal models for its immunomodulatory and antiviral effects, with reported oral bioavailability and distribution to various tissues. However, specific in vivo pharmacokinetic and pharmacodynamic data for the 6-methyl analog are not documented in the public literature. The compound's in vivo relevance is indirect, through the pharmaceutical agents synthesized from this building block.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, 6-methylpicolinic acid is not typically evaluated as a direct test compound. However, as a picolinic acid derivative, it may be studied for metal-binding properties using cell-free systems. Standard assay protocols involve incubating the compound with metal ions such as Zn²⁺, Fe²⁺, or Cu²⁺ in appropriate buffers (e.g., HEPES, Tris-HCl, pH 7.4) at 25-37°C. Metal binding is assessed using UV-visible spectroscopy, fluorescence quenching, or isothermal titration calorimetry (ITC). Competitive binding assays with known metal chelators such as EDTA or DTPA can be performed to determine relative binding affinities. The carboxylic acid and pyridine nitrogen are expected to participate in metal coordination.
|
| Cell Assay |
For in vitro cell-based assays, 6-methylpicolinic acid can be evaluated in cell viability and cytotoxicity studies using standard cell lines such as HeLa, HepG2, or Jurkat cells. Cells are seeded in 96-well plates and treated with the compound at concentrations ranging from 1-1000 μM for 24-72 hours. Cell viability is assessed using MTT or resazurin-based assays. Antiviral activity can be evaluated in virus-infected cell cultures (e.g., HIV-1 in MT-4 cells or influenza in MDCK cells) by measuring inhibition of viral replication via plaque reduction or reporter gene assays. Immunomodulatory effects can be assessed in macrophage cultures by measuring cytokine production (TNF-α, IL-6, IL-10) via ELISA following compound treatment.
|
| Animal Protocol |
In vivo animal studies for 6-methylpicolinic acid are not documented. For pharmaceutical agents synthesized from this intermediate, standard in vivo protocols involve administration to rodents (mice or rats) via oral gavage, intravenous injection, or intraperitoneal injection at doses determined from in vitro potency data. For antiviral or immunomodulatory candidates derived from picolinic acid analogs, efficacy studies would be conducted in appropriate disease models (e.g., viral challenge models, autoimmune disease models). Pharmacokinetic sampling would involve plasma collection at multiple time points for LC-MS/MS analysis. Specific protocols for this compound are not available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 6-methylpicolinic acid are not documented in the literature. As a small molecule with molecular weight approximately 137 g/mol, it is expected to have favorable permeability characteristics. Picolinic acid derivatives are generally water-soluble due to the carboxylic acid group and may be subject to renal excretion. The methyl group at the 6-position may influence metabolic stability and lipophilicity compared to the parent compound. However, specific empirical pharmacokinetic parameters such as half-life, clearance, volume of distribution, protein binding, and oral bioavailability are not available for this compound in the public domain.
|
| Toxicity/Toxicokinetics |
6-Methylpicolinic acid is a research chemical and should be handled with appropriate laboratory safety precautions. Picolinic acid derivatives may cause skin and eye irritation. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available for this compound in the public literature. Standard safety practices include the use of personal protective equipment (gloves, safety goggles, lab coat), working in a fume hood, and avoiding inhalation and skin contact. The compound is intended for research use only and not for human therapeutic or diagnostic applications.
|
| Additional Infomation |
6-Methylpicolinic acid (6-Methylpyridine-2-carboxylic acid) (CAS 934-60-1) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. It serves as a building block for the synthesis of various pharmacologically active compounds, including potential antiviral and immunomodulatory agents. Picolinic acid, the parent compound, is a naturally occurring metabolite of tryptophan and has been investigated for its antiviral, immunomodulatory, and neuroprotective properties. The methylated analog may offer altered physicochemical properties and biological activity profiles compared to the parent compound. No clinical trials or approved indications exist for 6-methylpicolinic acid. It is intended for laboratory research use only and not for human therapeutic or diagnostic applications.
|
| Molecular Formula |
C7H7NO2
|
|---|---|
| Molecular Weight |
137.14
|
| Exact Mass |
137.047
|
| CAS # |
934-60-1
|
| PubChem CID |
70282
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
283.6±20.0 °C at 760 mmHg
|
| Melting Point |
130 °C
|
| Flash Point |
125.3±21.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.561
|
| LogP |
0.36
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
136
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C=CC=C(C)N=1)O
|
| InChi Key |
LTUUGSGSUZRPRV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C7H7NO2/c1-5-3-2-4-6(8-5)7(9)10/h2-4H,1H3,(H,9,10)
|
| Chemical Name |
6-methylpyridine-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2918 mL | 36.4591 mL | 72.9182 mL | |
| 5 mM | 1.4584 mL | 7.2918 mL | 14.5836 mL | |
| 10 mM | 0.7292 mL | 3.6459 mL | 7.2918 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
